第三剂疫苗接种与必要工作人员抗体水平及副反应的关联:一项前瞻性队列研究
该前瞻性队列研究纳入392名20岁以上医护人员,随访2021年12月至2023年11月,评估第三剂BNT162b2新冠疫苗接种后抗体滴度变化与7天内不良反应的关系;结果显示接种后4周IgG几何均值从609 U/mL升至18735 U/mL(p<0.001),发热或接种部位肿胀与抗体滴度变化无统计学显著关联。
要点
- 第三剂BNT162b2接种后4周IgG几何均值由609 U/mL升至18735 U/mL(p<0.001)。
- 接种后发热或接种部位肿胀与抗体滴度变化无统计学显著关系。
- 年龄(1.02,95%CI 1.01-1.03)和高血压(0.66,95%CI 0.47-0.93)可能影响抗体滴度增长率。
核心结论
- 第三剂新冠疫苗加强接种后,发热或使用退热药等药物与抗体滴度变化无统计学显著差异。
研究设计与样本
- 前瞻性队列研究,随访期为2021年12月至2023年11月。
- 共纳入392名20岁以上在该机构工作且希望测量疫苗抗体滴度的医护人员。
- 接种第三剂BNT162b2新冠疫苗,评估接种前后抗体滴度变化及接种后不良反应。
主要发现
- 392人参与研究,其中358人测量了加强接种前后的抗体滴度。
- 总体IgG几何均值在加强接种前为609 U/mL(561-663),接种后4周升至18735 U/mL(17509-20049)(p<0.001)。
- 多因素分析显示,接种后发热或接种部位肿胀与抗体滴度变化等主要终点之间无统计学显著关系。
- 影响抗体滴度增长率的因素(作为次要终点评估)可能包括年龄(1.02,95%CI 1.01-1.03)和高血压(0.66,95%CI 0.47-0.93)。
关键数值与推荐
- 主要终点为第三剂新冠疫苗接种后7天内不良反应及接种后4周新冠疫苗抗体滴度增长率。
- 抗体滴度增长率的影响因素:年龄(1.02,95%CI 1.01-1.03)和高血压(0.66,95%CI 0.47-0.93)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the relationship between the change of titer and adverse events after the third vaccination for COVID-19 among healthcare workers. DESIGN AND SETTING: This was a prospective cohort study, and the follow-up period was from December 2021 to November 2023. PARTICIPANTS: A total of 392 healthcare workers aged over 20 years who worked at the facility and wished to have vaccine antibody titers measured participated in this study. EXPOSURES: A third dose of BNT162b2 COVID-19 vaccine was administered to healthcare workers working at the hospital, and we evaluated the changes in antibody titers before and after the vaccine, as well as adverse reactions after vaccination. MAIN OUTCOMES AND MEASURES: The primary endpoints were adverse reactions within 7 days after the third dose of COVID-19 vaccine and the rate of increase in COVID-19 vaccine antibody titer at 4 weeks. RESULTS: A total of 392 people participated in the study, of whom 358 participants had their antibody titers measured before and after the booster vaccination. The overall IgG geometric mean was 609 U/mL (561-663) before booster vaccination and increased to 18,735 U/mL (17,509-20,049) at 4 weeks after vaccination (p < 0.001). Multivariate analysis showed no statistically significant relationship between the primary endpoints, such as a change in antibody titer due to the presence of fever after vaccination or a change in antibody titer due to swelling at the vaccination site. Factors affecting the rate of increase in antibody titer, evaluated as secondary endpoints, were suggested to be age (1.02 (95 % confidence interval (CI): 1.01-1.03)) and hypertension (0.66 (95 % CI: 0.47-0.93)). CONCLUSIONS AND RELEVANCE: In relation to the booster effect of the third dose of COVID-19 vaccination, there was no statistically significant difference in the presence of fever or use of antipyretic or other drugs.
引用
- Hamada H, Futamura M, Ito H, et al. Association of a third vaccination with antibody levels and side reactions in essential workers: A prospective cohort study. Vaccine. 2023. PMID: 36737319. doi:10.1016/j.vaccine.2023.01.050
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。